<DOC>
	<DOCNO>NCT01945775</DOCNO>
	<brief_summary>The purpose open-label , 2:1 randomized phase III trial compare safety efficacy talazoparib ( also know BMN 673 ) versus protocol-specific physician 's choice patient locally advance and/or metastatic breast cancer germline BRCA mutation .</brief_summary>
	<brief_title>A Study Evaluating Talazoparib ( BMN 673 ) , PARP Inhibitor , Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation ( EMBRACA Study )</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Talazoparib</mesh_term>
	<mesh_term>Poly ( ADP-ribose ) Polymerase Inhibitors</mesh_term>
	<criteria>Histologically cytologically confirm carcinoma breast Locally advance breast cancer amenable curative radiation surgical cure and/or metastatic disease appropriate systemic single cytotoxic chemotherapy Documentation deleterious , suspect deleterious , pathogenic germline BRCA1 BRCA2 mutation Myriad Genetics laboratory approve Sponsor No 3 prior chemotherapyinclusive regimen locally advance and/or metastatic disease ( limit prior hormonal therapy target anticancer therapy mechanistic target rapamycin ( mTOR ) CDK4/6 inhibitor , immuneoncology agent , tyrosine kinase inhibitor , monoclonal antibody CTL4 VEGF ) Prior treatment taxane and/or anthracycline neoadjuvant , adjuvant , locally advanced , metastatic setting unless medically contraindicate Have measurable nonmeasurable , evaluable disease revise response evaluation criterion solid tumor ( RECIST ) v.1.1 Eastern Cooperative Oncology Group ( ECOG ) performance status ≤ 2 Firstline locally advance and/or metastatic breast cancer prior adjuvant chemotherapy unless Investigator determine one 4 cytotoxic chemotherapy agent control arm would otherwise offer subject Prior treatment PARP inhibitor ( include iniparib ) Not candidate treatment least 1 treatment protocolspecific physician 's choice ( ie , capecitabine , eribulin , gemcitabine , vinorelbine ) Subjects objective disease progression receive platinum chemotherapy administer locally advanced metastatic disease ; subject receive lowdose platinum therapy administer combination radiation therapy exclude Subjects receive platinum adjuvant neoadjuvant set eligible ; however , subject may relapse within 6 month last dose prior platinum therapy Cytotoxic chemotherapy within 14 day randomization Radiation antihormonal therapy target anticancer therapy within 14 day randomization HER2 positive breast cancer Active inflammatory breast cancer CNS metastases Exception : Adequately treat brain metastasis document baseline CT MRI scan progress since previous scan require corticosteroid ( except prednisone ≤ 5 mg/day equivalent ) management CNS symptom . A repeat CT MRI follow identification CNS metastasis ( obtain least 2 week definitive therapy ) must document adequately treated brain metastasis . Subjects leptomeningeal carcinomatosis permit Prior malignancy except follow : Prior BRCAassociated cancer long current evidence cancer Carcinoma situ nonmelanoma skin cancer A cancer diagnose definitively treat ≥ 5 year randomization subsequent evidence recurrence Known human immunodeficiency virus positive Known active hepatitis C virus , know active hepatitis B virus Known hypersensitivity component talazoparib</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>BRCA mutation</keyword>
	<keyword>PARP inhibitor</keyword>
	<keyword>BRCA 1</keyword>
	<keyword>BRCA 2</keyword>
</DOC>